Heart failure is a common and complex clinical syndrome that results from any functional or structural heart disorder, impairing ventricular filling or ejection of blood to the systemic circulation to meet the body's needs. Heart failure can be caused by diseases of the endocardium, myocardium, pericardium, heart valves, vessels or metabolic disorders. Most patients with Heart failure have symptoms due to impaired left ventricular myocardial function. Patients usually present with dyspnea and fatigue limiting exercise tolerance, fluid retention characterized by pulmonary and peripheral edema.
Heart failure due to left ventricular dysfunction is categorized according to left ventricular ejection fraction (LVEF) into heart failure with reduced ejection fraction (LVEF 40% or less), known as HFrEF and heart failure with preserved ejection fraction (LVEF greater than 40%); known as HFpEF.
Heart failure is caused by several disorders, including diseases affecting the pericardium, myocardium, endocardium, cardiac valves, vasculature, or metabolism.
The most common causes of systolic dysfunction (HFrEF) are idiopathic dilated cardiomyopathy (DCM), coronary heart disease (ischemic), hypertension, and valvular disease. For diastolic dysfunction (HFpEF), similar conditions have been described as common causes, adding hypertrophic obstructive cardiomyopathy, and restrictive cardiomyopathy.
Approximately 5.1 million people in the United States have clinically manifest heart failure, and the prevalence continues to increase. Heart failure incidence has remained stable over the past decades, with more than 650,000 new cases heart failure cases diagnosed annually, especially for individuals greater than 65 years of age. Because prevalence is greater in this age group, heart failure is expected to worsen in the future.Epidemiological differences have been noted. Black men have the highest incidence rate (1000 person-years) for heart failure and the greatest five-year mortality rate when compared to whites. White women represent the lowest incidence. Heart failure in non-Hispanic black males and females has a prevalence of 4.5% and 3.8%, respectively, versus 2.7% and 1.8% in non-Hispanic white males and females, respectively. Although survival has improved, the absolute mortality rates for patients with heart failure remain approximately 50% within five years of diagnosis.
By 2013, heart failure costs in the United States exceeded $30 billion.
The adaptive mechanisms that may be adequate to maintain the overall contractile performance of the heart at relatively normal levels become maladaptive when trying to sustain adequate cardiac performance. The primary myocardial response to chronically increased wall stress is myocyte hypertrophy, death due to apoptosis, and regeneration. This process eventually leads to remodeling, usually the eccentric type, and reduced cardiac output, causing a cascade of the neurohumoral and vascular mechanism.
Decreased carotid baroreceptor stimulation and renal perfusion will activate the sympathetic nervous system and Renin-Angiotensin-Aldosterone system.
Sympathetic nervous system activation will cause increased heart rate and inotropy, leading to myocardial toxicity. Renin-Angiotensin-Aldosterone system activation leads to vasoconstriction, increasing afterload (angiotensin II) and hemodynamic alterations, increasing preload (aldosterone).
All of these mechanisms will cause negative remodeling and worsen the left ventricular function, causing symptoms of heart failure.
Symptoms of heart failure include those due to excess fluid accumulation (dyspnea, orthopnea, edema, pain from hepatic congestion, and abdominal distention from ascites) and those due to a reduction in cardiac output (fatigue, weakness) that is most pronounced with physical exertion.
Acute and subacute presentations (days to weeks) are characterized by shortness of breath at rest and/or with exertion, orthopnea, paroxysmal nocturnal dyspnea, and right upper quadrant discomfort due to acute hepatic congestion (right heart failure). Palpitations, with or without lightheadedness can occur if patient develops atrial or ventricular tachyarrhythmias
Chronic presentations (months) differ in that fatigue, anorexia, abdominal distension, and peripheral edema may be more pronounced than dyspnea. The anorexia is secondary to several factors including a poor perfusion of the splanchnic circulation, bowel edema, and nausea induced by hepatic congestion.
Diuretics, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitor, hydralazine plus nitrate, digoxin, and aldosterone antagonists can produce an improvement in symptoms
Prolongation of patient survival has been documented with beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor neprilysin inhibitor, hydralazine plus nitrate, and aldosterone antagonists. More limited evidence of survival benefit is available for diuretic therapy. Replace an angiotensin converting enzyme inhibitors or angiotensin receptor blockers by angiotensin receptor neprilysin inhibitor in chronic symptomatic patients with CHF NYHA class II-III with an adequate blood pressure who are tolerating an optimal dose of these medications. Angiotensin receptor neprilysin inhibitor should not be given within 36 hrs of angiotensin converting enzyme inhibitors dose.
In African-Americans, hydralazine plus oral nitrate is indicated in patients with persistent NYHA class III to IV HF and LVEF less than 40%, despite optimal medical therapy (beta-blocker, angiotensin converting enzyme inhibitors, ARB, aldosterone antagonist (if indicated), and diuretics.
Device therapy: implantable cardioverter-defibrillator (ICD) is used for primary or secondary prevention of sudden cardiac death. Cardiac resynchronization therapy with biventricular pacing can improve symptoms and survival in selected patients who are in sinus rhythm and have a reduced left ventricular ejection fraction and a prolonged QRS duration. Most patients who satisfy criteria for cardiac resynchronization therapy implantation are also candidates for an implantable cardioverter-defibrillator and receive a combined device.
A ventricular assist device (bridge to transplant or as a destination therapy) or cardiac transplant are reserved for those with severe disease despite all other measures.
To reduce heart failure hospitalizations, it is reasonable (class IIa) to use Ivabradine in patients with NYHA II-III with guideline-directed medical therapy (including a beta-blocker) and heart rate of more than 70 bpm.
Heart failure disease management is a complex condition that requires a multidisciplinary framework for the care of patients, including discharge planning, patient education, and frequent outpatient assessment.
|||Kibari A,Cohen AD,Gazitt T,Bitterman H,Lavi I,Feldhamer I,Shalom G,Greenberg-Dotan S,Zisman D, Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study. Clinical rheumatology. 2019 Apr 1; [PubMed PMID: 30937638]|
|||Dieckelmann M,Reinhardt F,Jeitler K,Semlitsch T,Plath J,Gerlach FM,Siebenhofer A,Petersen JJ, Chronic heart failure patients' experiences of German healthcare services: a protocol for a scoping review. BMJ open. 2019 Feb 19; [PubMed PMID: 30782940]|
|||Han J,Trumble DR, Cardiac Assist Devices: Early Concepts, Current Technologies, and Future Innovations. Bioengineering (Basel, Switzerland). 2019 Feb 15; [PubMed PMID: 30781387]|
|||Kim MS,Lee JH,Cho HJ,Cho JY,Choi JO,Hwang KK,Yoo BS,Kang SM,Choi DJ, KSHF Guidelines for the Management of Acute Heart Failure: Part III. Specific Management of Acute Heart Failure According to the Etiology and Co-morbidity. Korean circulation journal. 2019 Jan; [PubMed PMID: 30637995]|
|||Iyngkaran P,Liew D,Neil C,Driscoll A,Marwick TH,Hare DL, Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age. Clinical Medicine Insights. Cardiology. 2018; [PubMed PMID: 30618487]|
|||Dokainish H,Teo K,Zhu J,Roy A,AlHabib KF,ElSayed A,Palileo-Villaneuva L,Lopez-Jaramillo P,Karaye K,Yusoff K,Orlandini A,Sliwa K,Mondo C,Lanas F,Prabhakaran D,Badr A,Elmaghawry M,Damasceno A,Tibazarwa K,Belley-Cote E,Balasubramanian K,Islam S,Yacoub MH,Huffman MD,Harkness K,Grinvalds A,McKelvie R,Bangdiwala SI,Yusuf S, Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. The Lancet. Global health. 2017 Jul; [PubMed PMID: 28476564]|
|||Roston TM,Chua D,Lum E,Krahn AD, Switching Between β-Blockers: An Empiric Tool for the Cardiovascular Practitioner. The Canadian journal of cardiology. 2019 Apr; [PubMed PMID: 30935645]|
|||Komajda M,Schöpe J,Wagenpfeil S,Tavazzi L,Böhm M,Ponikowski P,Anker SD,Filippatos GS,Cowie MR, Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. European journal of heart failure. 2019 Apr 1; [PubMed PMID: 30933403]|
|||Bozkurt B, Target Dose Versus Maximum Tolerated Dose in Heart Failure: Time to Calibrate and Define Actionable Goals. JACC. Heart failure. 2019 Apr; [PubMed PMID: 30922510]|
|||Healy L,Ledwidge M,Gallagher J,Watson C,McDonald K, Developing a disease management program for the improvement of heart failure outcomes: the do's and the don'ts. Expert review of cardiovascular therapy. 2019 Mar 27; [PubMed PMID: 30916595]|
|||Spinar J,Spinarova L,Malek F,Ludka O,Krejci J,Ostadal P,Vondrakova D,Labr K,Spinarova M,Pavkova Goldbergova M,Benesova K,Jarkovsky J,Parenica J, Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry. PloS one. 2019; [PubMed PMID: 30913251]|
|||Costanzo MR, Ultrafiltration in Acute Heart Failure. Cardiac failure review. 2019 Feb; [PubMed PMID: 30847239]|
|||Larina VN,Chukaeva II,Larin VG, Current Trends and Possibilities of Providing Medical Palliative Care in Chronic Heart Failure. Kardiologiia. 2019 Jan 28; [PubMed PMID: 30710994]|
|||Sathyamurthy I,Newale S, Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications. Indian heart journal. 2018 Dec; [PubMed PMID: 30595304]|
|||Ali A,Abu Zar M,Kamal A,Faquih AE,Bhan C,Iftikhar W,Malik MB,Ahmad MQ,Ali NS,Sami SA,Jitidhar F,Cheema AM,Zulfiqar A, American Heart Association High Blood Pressure Protocol 2017: A Literature Review. Cureus. 2018 Aug 29; [PubMed PMID: 30410836]|
|||Vinogradova NG, City Center for the Treatment of Chronic Heart Failure: the organiza-tion of work and the effectiveness of treatment of patients with chronic heart failure. Kardiologiia. 2019 Mar 7; [PubMed PMID: 30853011]|
|||Edvinsson ML,Stenberg A,Åström-Olsson K, Improved outcome with standardized plan for clinical management of acute decompensated chronic heart failure. Journal of geriatric cardiology : JGC. 2019 Jan; [PubMed PMID: 30800146]|
|||Shu Q,Wu L,Zhang R,Zhang Q,Huang J,Meng Y, Age-dependent changes in cardiac performance, motor function, QoL, and mental status in metoprolol-treated chronic heart failure patients. Scientific reports. 2019 Jan 24; [PubMed PMID: 30679746]|